New Uses for Old Drugs in HIV Infection View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

1999-12

AUTHORS

Elisabetta Ravot, Julianna Lisziewicz, Franco Lori

ABSTRACT

The tenacious effort to develop new, specific agents to treat HIV infection is currently accompanied by a reconsideration of existing drugs on the basis of their known or putative effects on the retroviral life cycle and/or the tuning of immune mechanisms.Three specific ‘older’ compounds that interfere with HIV infection by both a direct antiviral activity, and a modulation of T-cell activation and proliferation have received the most attention.Hydroxurea, a classical chemotherapeutic agent, inhibits retroviral reverse transcription by targeting a cellular enzyme responsible for the synthesis of deoxynucleoside triphosphates. It may also have a role in reducing viral load while maintaining low numbers of potential target T cells. Beneficial effects of hydroxyurea in combination with didanosine and/or stavudine on viral load have been shown in a number of clinical trials.Cyclosporin, a known immunosuppresant, blocks the activation of T cells, hence reducing the permissivity to HIV, and also prevents proper HIV virion maturation. However, clinical studies have produced conflicting results in HIV-infected patients with regard to immunological and disease effects and toxicity.Thalidomide may have antiretroviral effects as a result of its primarily inhibitory effects on the production of tumour necrosis factor α (TNFα). TNFα induces expression of HIV from chronically infected cell lines by stimulating a cellular transcription factor, and blocking of TNFα-stimulated HIV replication by thalidomide has been shown in vitro and ex vivo. However, the effects on TNFa production in vivo have been inconsistent. Thalidomide has shown potential in treating some AIDS-related conditions [cachexia (weight loss and muscle wasting), and aphtous oral, oesophageal or genital ulcers]. However, because of its numerous and major adverse effects, thalidomide should always be used cautiously.In summary, some older drugs have potential as anti-HIV agents and offer the advantage of extensive clinical experience in other therapeutic areas. They should be considered as potential partners for the products emerging from more recent research and development. More... »

PAGES

953-963

Identifiers

URI

http://scigraph.springernature.com/pub.10.2165/00003495-199958060-00001

DOI

http://dx.doi.org/10.2165/00003495-199958060-00001

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1016258438

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/10651384


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1108", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical Microbiology", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cyclosporine", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "HIV Infections", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Hydroxyurea", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Immunosuppressive Agents", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Nucleic Acid Synthesis Inhibitors", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Thalidomide", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Research Institute for Genetic and Human Therapy (RIGHT), Policlinico San Matteo, Padiglione Forlanini, P.le Golgi, 2-27100, Pavia, Italy", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Research Institute for Genetic and Human Therapy (RIGHT), Policlinico San Matteo, Padiglione Forlanini, P.le Golgi, 2-27100, Pavia, Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Ravot", 
        "givenName": "Elisabetta", 
        "id": "sg:person.0663364021.18", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0663364021.18"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Research Institute for Genetic and Human Therapy (RIGHT), I.R.C.C.S., Washington DC, USA", 
          "id": "http://www.grid.ac/institutes/grid.437555.5", 
          "name": [
            "Research Institute for Genetic and Human Therapy (RIGHT), I.R.C.C.S., Washington DC, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Lisziewicz", 
        "givenName": "Julianna", 
        "id": "sg:person.01351340721.14", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01351340721.14"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Research Institute for Genetic and Human Therapy (RIGHT), Policlinico San Matteo, Padiglione Forlanini, P.le Golgi, 2-27100, Pavia, Italy", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Research Institute for Genetic and Human Therapy (RIGHT), Policlinico San Matteo, Padiglione Forlanini, P.le Golgi, 2-27100, Pavia, Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Lori", 
        "givenName": "Franco", 
        "id": "sg:person.01201463615.72", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01201463615.72"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1007/978-1-4615-1995-9_20", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1022430872", 
          "https://doi.org/10.1007/978-1-4615-1995-9_20"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1023/a:1011924314899", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1047276096", 
          "https://doi.org/10.1023/a:1011924314899"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/bf03401576", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1082842600", 
          "https://doi.org/10.1007/bf03401576"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/17401", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1013680268", 
          "https://doi.org/10.1038/17401"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.2165/00002018-199512060-00002", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1010948128", 
          "https://doi.org/10.2165/00002018-199512060-00002"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/372363a0", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1033919459", 
          "https://doi.org/10.1038/372363a0"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "1999-12", 
    "datePublishedReg": "1999-12-01", 
    "description": "The tenacious effort to develop new, specific agents to treat HIV infection is currently accompanied by a reconsideration of existing drugs on the basis of their known or putative effects on the retroviral life cycle and/or the tuning of immune mechanisms.Three specific \u2018older\u2019 compounds that interfere with HIV infection by both a direct antiviral activity, and a modulation of T-cell activation and proliferation have received the most attention.Hydroxurea, a classical chemotherapeutic agent, inhibits retroviral reverse transcription by targeting a cellular enzyme responsible for the synthesis of deoxynucleoside triphosphates. It may also have a role in reducing viral load while maintaining low numbers of potential target T cells. Beneficial effects of hydroxyurea in combination with didanosine and/or stavudine on viral load have been shown in a number of clinical trials.Cyclosporin, a known immunosuppresant, blocks the activation of T cells, hence reducing the permissivity to HIV, and also prevents proper HIV virion maturation. However, clinical studies have produced conflicting results in HIV-infected patients with regard to immunological and disease effects and toxicity.Thalidomide may have antiretroviral effects as a result of its primarily inhibitory effects on the production of tumour necrosis factor \u03b1 (TNF\u03b1). TNF\u03b1 induces expression of HIV from chronically infected cell lines by stimulating a cellular transcription factor, and blocking of TNF\u03b1-stimulated HIV replication by thalidomide has been shown in vitro and ex vivo. However, the effects on TNFa production in vivo have been inconsistent. Thalidomide has shown potential in treating some AIDS-related conditions [cachexia (weight loss and muscle wasting), and aphtous oral, oesophageal or genital ulcers]. However, because of its numerous and major adverse effects, thalidomide should always be used cautiously.In summary, some older drugs have potential as anti-HIV agents and offer the advantage of extensive clinical experience in other therapeutic areas. They should be considered as potential partners for the products emerging from more recent research and development.", 
    "genre": "article", 
    "id": "sg:pub.10.2165/00003495-199958060-00001", 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1084788", 
        "issn": [
          "0012-6667", 
          "1179-1950"
        ], 
        "name": "Drugs", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "6", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "58"
      }
    ], 
    "keywords": [
      "HIV infection", 
      "viral load", 
      "T cells", 
      "old drugs", 
      "tumor necrosis factor \u03b1", 
      "major adverse effects", 
      "direct antiviral activity", 
      "TNF\u03b1-induced expression", 
      "target T cells", 
      "necrosis factor \u03b1", 
      "extensive clinical experience", 
      "T cell activation", 
      "classical chemotherapeutic agents", 
      "antiretroviral effect", 
      "HIV replication", 
      "immune mechanisms", 
      "clinical trials", 
      "clinical studies", 
      "TNFa production", 
      "retroviral reverse transcription", 
      "clinical experience", 
      "chemotherapeutic agents", 
      "factor \u03b1", 
      "antiviral activity", 
      "ex vivo", 
      "HIV agents", 
      "HIV", 
      "beneficial effects", 
      "specific agents", 
      "thalidomide", 
      "inhibitory effect", 
      "adverse effects", 
      "infection", 
      "therapeutic areas", 
      "induces expression", 
      "putative effects", 
      "drugs", 
      "cell lines", 
      "disease effects", 
      "cellular transcription factors", 
      "retroviral life cycle", 
      "reverse transcription", 
      "vivo", 
      "cellular enzymes", 
      "activation", 
      "agents", 
      "virion maturation", 
      "low number", 
      "cells", 
      "immunosuppresants", 
      "didanosine", 
      "patients", 
      "stavudine", 
      "transcription factors", 
      "TNF\u03b1", 
      "cyclosporin", 
      "AIDS", 
      "trials", 
      "effect", 
      "hydroxurea", 
      "vitro", 
      "hydroxyurea", 
      "permissivity", 
      "proliferation", 
      "toxicity", 
      "maturation", 
      "deoxynucleoside triphosphates", 
      "expression", 
      "modulation", 
      "triphosphate", 
      "factors", 
      "recent research", 
      "activity", 
      "replication", 
      "summary", 
      "study", 
      "role", 
      "number", 
      "new uses", 
      "transcription", 
      "enzyme", 
      "experience", 
      "production", 
      "most attention", 
      "results", 
      "mechanism", 
      "regard", 
      "combination", 
      "partners", 
      "development", 
      "lines", 
      "potential", 
      "area", 
      "life cycle", 
      "compounds", 
      "uses", 
      "efforts", 
      "cycle", 
      "load", 
      "basis", 
      "research", 
      "conditions", 
      "potential partners", 
      "attention", 
      "reconsideration", 
      "synthesis", 
      "products", 
      "advantages", 
      "tenacious efforts", 
      "tuning"
    ], 
    "name": "New Uses for Old Drugs in HIV Infection", 
    "pagination": "953-963", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1016258438"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.2165/00003495-199958060-00001"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "10651384"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.2165/00003495-199958060-00001", 
      "https://app.dimensions.ai/details/publication/pub.1016258438"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-12-01T06:22", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20221201/entities/gbq_results/article/article_313.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.2165/00003495-199958060-00001"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.2165/00003495-199958060-00001'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.2165/00003495-199958060-00001'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.2165/00003495-199958060-00001'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.2165/00003495-199958060-00001'


 

This table displays all metadata directly associated to this object as RDF triples.

244 TRIPLES      21 PREDICATES      150 URIs      135 LITERALS      14 BLANK NODES

Subject Predicate Object
1 sg:pub.10.2165/00003495-199958060-00001 schema:about N1f900648e4514431b3a7a949ef6fb120
2 N51946d20413d4f5e8ffb3fafbe398d3d
3 Nb6b9b89f1d374a13bf7878bb0c3fcf66
4 Nea28d05746964935a1bbe24575520b99
5 Nf3dfdb7816be4b0ab483e1f405ba2f53
6 Nf48b42bf8e3d4268b2d7501fd8c2f012
7 Nfe27884fb0164cafac73582dd2be3495
8 anzsrc-for:11
9 anzsrc-for:1103
10 anzsrc-for:1108
11 schema:author N216503acb31746d28068631b9295ba30
12 schema:citation sg:pub.10.1007/978-1-4615-1995-9_20
13 sg:pub.10.1007/bf03401576
14 sg:pub.10.1023/a:1011924314899
15 sg:pub.10.1038/17401
16 sg:pub.10.1038/372363a0
17 sg:pub.10.2165/00002018-199512060-00002
18 schema:datePublished 1999-12
19 schema:datePublishedReg 1999-12-01
20 schema:description The tenacious effort to develop new, specific agents to treat HIV infection is currently accompanied by a reconsideration of existing drugs on the basis of their known or putative effects on the retroviral life cycle and/or the tuning of immune mechanisms.Three specific ‘older’ compounds that interfere with HIV infection by both a direct antiviral activity, and a modulation of T-cell activation and proliferation have received the most attention.Hydroxurea, a classical chemotherapeutic agent, inhibits retroviral reverse transcription by targeting a cellular enzyme responsible for the synthesis of deoxynucleoside triphosphates. It may also have a role in reducing viral load while maintaining low numbers of potential target T cells. Beneficial effects of hydroxyurea in combination with didanosine and/or stavudine on viral load have been shown in a number of clinical trials.Cyclosporin, a known immunosuppresant, blocks the activation of T cells, hence reducing the permissivity to HIV, and also prevents proper HIV virion maturation. However, clinical studies have produced conflicting results in HIV-infected patients with regard to immunological and disease effects and toxicity.Thalidomide may have antiretroviral effects as a result of its primarily inhibitory effects on the production of tumour necrosis factor α (TNFα). TNFα induces expression of HIV from chronically infected cell lines by stimulating a cellular transcription factor, and blocking of TNFα-stimulated HIV replication by thalidomide has been shown in vitro and ex vivo. However, the effects on TNFa production in vivo have been inconsistent. Thalidomide has shown potential in treating some AIDS-related conditions [cachexia (weight loss and muscle wasting), and aphtous oral, oesophageal or genital ulcers]. However, because of its numerous and major adverse effects, thalidomide should always be used cautiously.In summary, some older drugs have potential as anti-HIV agents and offer the advantage of extensive clinical experience in other therapeutic areas. They should be considered as potential partners for the products emerging from more recent research and development.
21 schema:genre article
22 schema:isAccessibleForFree false
23 schema:isPartOf Na44cb6ba267848beaaba0c22fa811d84
24 Na8e12503ccf74408abe46f7512798029
25 sg:journal.1084788
26 schema:keywords AIDS
27 HIV
28 HIV agents
29 HIV infection
30 HIV replication
31 T cell activation
32 T cells
33 TNFa production
34 TNFα
35 TNFα-induced expression
36 activation
37 activity
38 advantages
39 adverse effects
40 agents
41 antiretroviral effect
42 antiviral activity
43 area
44 attention
45 basis
46 beneficial effects
47 cell lines
48 cells
49 cellular enzymes
50 cellular transcription factors
51 chemotherapeutic agents
52 classical chemotherapeutic agents
53 clinical experience
54 clinical studies
55 clinical trials
56 combination
57 compounds
58 conditions
59 cycle
60 cyclosporin
61 deoxynucleoside triphosphates
62 development
63 didanosine
64 direct antiviral activity
65 disease effects
66 drugs
67 effect
68 efforts
69 enzyme
70 ex vivo
71 experience
72 expression
73 extensive clinical experience
74 factor α
75 factors
76 hydroxurea
77 hydroxyurea
78 immune mechanisms
79 immunosuppresants
80 induces expression
81 infection
82 inhibitory effect
83 life cycle
84 lines
85 load
86 low number
87 major adverse effects
88 maturation
89 mechanism
90 modulation
91 most attention
92 necrosis factor α
93 new uses
94 number
95 old drugs
96 partners
97 patients
98 permissivity
99 potential
100 potential partners
101 production
102 products
103 proliferation
104 putative effects
105 recent research
106 reconsideration
107 regard
108 replication
109 research
110 results
111 retroviral life cycle
112 retroviral reverse transcription
113 reverse transcription
114 role
115 specific agents
116 stavudine
117 study
118 summary
119 synthesis
120 target T cells
121 tenacious efforts
122 thalidomide
123 therapeutic areas
124 toxicity
125 transcription
126 transcription factors
127 trials
128 triphosphate
129 tumor necrosis factor α
130 tuning
131 uses
132 viral load
133 virion maturation
134 vitro
135 vivo
136 schema:name New Uses for Old Drugs in HIV Infection
137 schema:pagination 953-963
138 schema:productId N1ff0a546c0124d24a39dae132a12d7aa
139 N558f1e15c255476b83044adaf05af019
140 Nf1763b6511984ce285f9ac2e6f1b7d57
141 schema:sameAs https://app.dimensions.ai/details/publication/pub.1016258438
142 https://doi.org/10.2165/00003495-199958060-00001
143 schema:sdDatePublished 2022-12-01T06:22
144 schema:sdLicense https://scigraph.springernature.com/explorer/license/
145 schema:sdPublisher N06a7253648984635b933289160c0485b
146 schema:url https://doi.org/10.2165/00003495-199958060-00001
147 sgo:license sg:explorer/license/
148 sgo:sdDataset articles
149 rdf:type schema:ScholarlyArticle
150 N06a7253648984635b933289160c0485b schema:name Springer Nature - SN SciGraph project
151 rdf:type schema:Organization
152 N1f900648e4514431b3a7a949ef6fb120 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
153 schema:name HIV Infections
154 rdf:type schema:DefinedTerm
155 N1ff0a546c0124d24a39dae132a12d7aa schema:name dimensions_id
156 schema:value pub.1016258438
157 rdf:type schema:PropertyValue
158 N216503acb31746d28068631b9295ba30 rdf:first sg:person.0663364021.18
159 rdf:rest N66fac3289562483ca8716e7d6b68c903
160 N22ec74eb387547db92e5e66d51b4a58e rdf:first sg:person.01201463615.72
161 rdf:rest rdf:nil
162 N51946d20413d4f5e8ffb3fafbe398d3d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
163 schema:name Hydroxyurea
164 rdf:type schema:DefinedTerm
165 N558f1e15c255476b83044adaf05af019 schema:name pubmed_id
166 schema:value 10651384
167 rdf:type schema:PropertyValue
168 N66fac3289562483ca8716e7d6b68c903 rdf:first sg:person.01351340721.14
169 rdf:rest N22ec74eb387547db92e5e66d51b4a58e
170 Na44cb6ba267848beaaba0c22fa811d84 schema:issueNumber 6
171 rdf:type schema:PublicationIssue
172 Na8e12503ccf74408abe46f7512798029 schema:volumeNumber 58
173 rdf:type schema:PublicationVolume
174 Nb6b9b89f1d374a13bf7878bb0c3fcf66 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
175 schema:name Nucleic Acid Synthesis Inhibitors
176 rdf:type schema:DefinedTerm
177 Nea28d05746964935a1bbe24575520b99 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
178 schema:name Thalidomide
179 rdf:type schema:DefinedTerm
180 Nf1763b6511984ce285f9ac2e6f1b7d57 schema:name doi
181 schema:value 10.2165/00003495-199958060-00001
182 rdf:type schema:PropertyValue
183 Nf3dfdb7816be4b0ab483e1f405ba2f53 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
184 schema:name Immunosuppressive Agents
185 rdf:type schema:DefinedTerm
186 Nf48b42bf8e3d4268b2d7501fd8c2f012 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
187 schema:name Cyclosporine
188 rdf:type schema:DefinedTerm
189 Nfe27884fb0164cafac73582dd2be3495 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
190 schema:name Humans
191 rdf:type schema:DefinedTerm
192 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
193 schema:name Medical and Health Sciences
194 rdf:type schema:DefinedTerm
195 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
196 schema:name Clinical Sciences
197 rdf:type schema:DefinedTerm
198 anzsrc-for:1108 schema:inDefinedTermSet anzsrc-for:
199 schema:name Medical Microbiology
200 rdf:type schema:DefinedTerm
201 sg:journal.1084788 schema:issn 0012-6667
202 1179-1950
203 schema:name Drugs
204 schema:publisher Springer Nature
205 rdf:type schema:Periodical
206 sg:person.01201463615.72 schema:affiliation grid-institutes:None
207 schema:familyName Lori
208 schema:givenName Franco
209 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01201463615.72
210 rdf:type schema:Person
211 sg:person.01351340721.14 schema:affiliation grid-institutes:grid.437555.5
212 schema:familyName Lisziewicz
213 schema:givenName Julianna
214 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01351340721.14
215 rdf:type schema:Person
216 sg:person.0663364021.18 schema:affiliation grid-institutes:None
217 schema:familyName Ravot
218 schema:givenName Elisabetta
219 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0663364021.18
220 rdf:type schema:Person
221 sg:pub.10.1007/978-1-4615-1995-9_20 schema:sameAs https://app.dimensions.ai/details/publication/pub.1022430872
222 https://doi.org/10.1007/978-1-4615-1995-9_20
223 rdf:type schema:CreativeWork
224 sg:pub.10.1007/bf03401576 schema:sameAs https://app.dimensions.ai/details/publication/pub.1082842600
225 https://doi.org/10.1007/bf03401576
226 rdf:type schema:CreativeWork
227 sg:pub.10.1023/a:1011924314899 schema:sameAs https://app.dimensions.ai/details/publication/pub.1047276096
228 https://doi.org/10.1023/a:1011924314899
229 rdf:type schema:CreativeWork
230 sg:pub.10.1038/17401 schema:sameAs https://app.dimensions.ai/details/publication/pub.1013680268
231 https://doi.org/10.1038/17401
232 rdf:type schema:CreativeWork
233 sg:pub.10.1038/372363a0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1033919459
234 https://doi.org/10.1038/372363a0
235 rdf:type schema:CreativeWork
236 sg:pub.10.2165/00002018-199512060-00002 schema:sameAs https://app.dimensions.ai/details/publication/pub.1010948128
237 https://doi.org/10.2165/00002018-199512060-00002
238 rdf:type schema:CreativeWork
239 grid-institutes:None schema:alternateName Research Institute for Genetic and Human Therapy (RIGHT), Policlinico San Matteo, Padiglione Forlanini, P.le Golgi, 2-27100, Pavia, Italy
240 schema:name Research Institute for Genetic and Human Therapy (RIGHT), Policlinico San Matteo, Padiglione Forlanini, P.le Golgi, 2-27100, Pavia, Italy
241 rdf:type schema:Organization
242 grid-institutes:grid.437555.5 schema:alternateName Research Institute for Genetic and Human Therapy (RIGHT), I.R.C.C.S., Washington DC, USA
243 schema:name Research Institute for Genetic and Human Therapy (RIGHT), I.R.C.C.S., Washington DC, USA
244 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...